10.70
+0.07(+0.66%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
188
First IPO Date
June 07, 1996
| Name | Title | Pay | Year Born |
| Mr. Gregory J. Divis Jr. | Chief Executive Officer & Director | 677,400 | 1967 |
| Mr. Thomas S. McHugh | Senior Vice President, Principal Financial & Accounting Officer and Chief Financial Officer | 530,119 | 1965 |
| Mr. Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer | 634,700 | 1974 |
| Dr. Jordan S. Dubow M.D. | Consultant | 727,933 | 1979 |
| Ms. Jennifer Gudeman PharmD | Senior Vice President of Medical & Clinical Affairs | 0 | N/A |
| Mr. Gregory J. Davis | Vice President of Corporate and Business Development | 0 | 1965 |
| Ms. Angie Woods | Vice President of People & Culture | 0 | N/A |
| Mr. Mark W. Elrod | Vice President of Sales | 0 | N/A |
| Dr. Jason M. Vaughn | Senior Vice President of Technical Operations | 0 | N/A |
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.